If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solutionThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Ramucirumab is a human VEGFR-2 antagonist indicated
as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or GEJ adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy
in combination with erlotinib, for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations
in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy
patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab
in combination with FOLFIRI, for the treatment of mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and
as a single agent, for the treatment of HCC in patients who have an AFP ≥400 ng/mL and have been treated with sorafenib.1
Enclosed Prescribing Information
CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly
1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
AFP = alpha-fetoprotein
ALK = anaplastic lymphoma kinase
EGFR = epidermal growth factor receptor
FDA = Food and Drug Administration
FOLFIRI = irinotecan, folinic acid, and 5-fluorouracil
GEJ = gastroesophageal junction
HCC = hepatocellular carcinoma
mCRC = metastatic colorectal cancer
NSCLC = non-small cell lung cancer
VEGFR-2 = vascular endothelial growth factor receptor 2
Date of Last Review: May 05, 2020
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST